{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:20:10Z","timestamp":1777418410705,"version":"3.51.4"},"reference-count":81,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review the contemporary role of the glycoprotein (GYP) IIb\/IIIa receptor inhibitors abciximab, eptifibatide, and tirofiban in patients undergoing percutaneous coronary intervention (PCI) and those with an acute coronary syndrome (ACS), and to provide an algorithm based on currently available evidence for specific agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Primary articles were identified by a MEDLINE search (1966\u2013January 2003); references cited in these articles provided additional resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>All of the articles identified from data sources were considered for relevant information; this article primarily addresses large, controlled or comparative studies, and meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>The role of GYP IIb\/IIIa inhibitors in patients undergoing PCI and those with ACS has progressed markedly. To date, abciximab has the most robust data in patients undergoing PCI, particularly high-risk individuals. In PCI patients with lower risk (e.g., elective stenting), eptifibatide is a reasonable first-line option. Data do not support tirofiban for routine use in patients undergoing PCI. For individuals with signs and symptoms of ACS, specifically unstable angina or non\u2013ST-segment elevation myocardial infarction (MI), eptifibatide or tirofiban is recommended in high-risk patients when a conservative approach is used (PCI is not planned). Abciximab is not recommended in this situation. In patients with ST-segment elevation MI (STEMI), abciximab is the only GYP IIb\/IIIa inhibitor evaluated in large, well-designed investigations. For medical management in combination with a fibrinolytic agent, the role of abciximab remains unclear. For patients undergoing primary PCI for the management of STEMI, the available evidence supports the use of abciximab, albeit further investigation is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The role of GYP IIb\/IIIa inhibitors in clinical cardiology continues to evolve. Choice of the agent depends on situation of use, patient-specific characteristics and risk stratification, and, in the case of ACS, chosen management strategy (medical management or intervention).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c338","type":"journal-article","created":{"date-parts":[[2003,5,8]],"date-time":"2003-05-08T13:30:50Z","timestamp":1052400650000},"page":"860-875","source":"Crossref","is-referenced-by-count":9,"title":["Glycoprotein IIb\/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome"],"prefix":"10.1177","volume":"37","author":[{"given":"Michael A","family":"Crouch","sequence":"first","affiliation":[{"name":"Michael A Crouch PharmD BCPS, Assistant Professor of Pharmacy and Medicine, Department of Pharmacy, Virginia Commonwealth University \u2014 MCV Campus, Richmond, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M","family":"Nappi","sequence":"additional","affiliation":[{"name":"Jean M Nappi PharmD FCCP BCPS, Professor of Pharmacy, Department of Pharmacy Practice, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai I","family":"Cheang","sequence":"additional","affiliation":[{"name":"Kai I Cheang PharmD BCPS, Assistant Professor of Pharmacy, Department of Pharmacy, Virginia Commonwealth University \u2014 MCV Campus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"bibr1-aph.1C338","first-page":"3828","volume":"96","author":"Coller BS","year":"1997","journal-title":"Circulation"},{"key":"bibr2-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00979-7"},{"key":"bibr3-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442502"},{"key":"bibr4-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/hc3301.094533"},{"key":"bibr5-aph.1C338","volume-title":"Package insert. ReoPro (abciximab)","year":"2001"},{"key":"bibr6-aph.1C338","volume-title":"Package insert. Integrilin (eptifibatide)","year":"2001"},{"key":"bibr7-aph.1C338","volume-title":"Package insert. Aggrastat (tirofiban)","year":"2002"},{"key":"bibr8-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.1.198"},{"key":"bibr9-aph.1C338","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"Use of monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","year":"1994","journal-title":"N Engl J Med"},{"key":"bibr10-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90007-8"},{"key":"bibr11-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01145-2"},{"key":"bibr12-aph.1C338","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","volume":"336","author":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","year":"1997","journal-title":"N Engl J Med"},{"key":"bibr13-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.15.1951"},{"key":"bibr14-aph.1C338","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","volume":"349","author":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","year":"1997","journal-title":"Lancet"},{"key":"bibr15-aph.1C338","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","volume":"352","author":"Randomised placebo-controlled and balloon-angioplasty\u2013controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","year":"1998","journal-title":"Lancet"},{"key":"bibr16-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10018-7"},{"key":"bibr17-aph.1C338","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","author":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","year":"1997","journal-title":"Circulation"},{"key":"bibr18-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"bibr19-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"bibr20-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)90158-1"},{"key":"bibr21-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907293410503"},{"key":"bibr22-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02319-0"},{"key":"bibr23-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09605-8"},{"key":"bibr24-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)80091-2"},{"key":"bibr25-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.5.618"},{"key":"bibr26-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1488"},{"key":"bibr27-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1757"},{"key":"bibr28-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02560-2"},{"key":"bibr29-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.24.2386"},{"key":"bibr30-aph.1C338","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","volume":"338","author":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina","year":"1998","journal-title":"N Engl J Med"},{"key":"bibr31-aph.1C338","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","author":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non\u2013Q-wave infarction","year":"1998","journal-title":"N Engl J Med"},{"key":"bibr32-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"bibr33-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05060-1"},{"key":"bibr34-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/hc0302.102573"},{"key":"bibr35-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442501"},{"key":"bibr36-aph.1C338","unstructured":"Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS,  ACC\/AHA guideline update for the management of patients with unstable angina and non\u2013ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. www.acc.org\/clinical\/guidelines\/unstable\/unstable.pdf (accessed 2003 Jan 25)."},{"key":"bibr37-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07442-1"},{"key":"bibr38-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000046487.06811.5E"},{"key":"bibr39-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07349-3"},{"key":"bibr40-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02427-2"},{"key":"bibr41-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09894-X"},{"key":"bibr42-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90041-X"},{"key":"bibr43-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.4.846"},{"key":"bibr44-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00474-4"},{"key":"bibr45-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00038-8"},{"key":"bibr46-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.21.2720"},{"key":"bibr47-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2243"},{"key":"bibr48-aph.1C338","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/01.CIR.101.24.2788","volume":"101","author":"Trial of abciximab with and without low-dose reteplase for acute myocardial infarction","year":"2000","journal-title":"Circulation"},{"key":"bibr49-aph.1C338","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.CIR.104.7.e34","volume":"104","author":"Giugliano RP","year":"2001","journal-title":"Circulation"},{"key":"bibr50-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01758-2"},{"key":"bibr51-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05059-5"},{"key":"bibr52-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05775-0"},{"key":"bibr53-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.17.2130"},{"key":"bibr54-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013402.34759.46"},{"key":"bibr55-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00128-2"},{"key":"bibr56-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00463-X"},{"key":"bibr57-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.24.2695"},{"key":"bibr58-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00635-X"},{"key":"bibr59-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008103430602"},{"key":"bibr60-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02187-7"},{"key":"bibr61-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.8.734"},{"key":"bibr62-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442503"},{"key":"bibr63-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013404"},{"key":"bibr64-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70302-3"},{"key":"bibr65-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.113391"},{"key":"bibr66-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2543"},{"key":"bibr67-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1293"},{"key":"bibr68-aph.1C338","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","year":"2001","journal-title":"N Engl J Med"},{"key":"bibr69-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"bibr70-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"bibr71-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00171-0"},{"issue":"2","key":"bibr72-aph.1C338","first-page":"II-826","volume":"102","author":"Cohen M","year":"2000","journal-title":"Circulation"},{"key":"bibr73-aph.1C338","doi-asserted-by":"crossref","first-page":"365A","DOI":"10.1016\/S0735-1097(01)80005-X","volume":"37","author":"Ferguson JJ","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"bibr74-aph.1C338","first-page":"E14","volume":"12","author":"Young JJ","year":"2000","journal-title":"J Invas Cardiol"},{"key":"bibr75-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.113217"},{"key":"bibr76-aph.1C338","unstructured":"Wallentin LC. GUSTO-IV ACS (Global Utilisation of Streptokinase and t-PA for Occluded coronary arteries Trial IV in Acute Coronary Syndromes): substudy comparing outcomes for the combination of abciximab with standard unfractionated heparin or low molecular weight heparin. Presented at: 22nd Congress of the European Society of Cardiology, Amsterdam, August 28, 2000."},{"key":"bibr77-aph.1C338","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/hc2901.094150","volume":"104","author":"Bhatt DL","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"bibr78-aph.1C338","first-page":"II-706","volume":"104","author":"Choussat R","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"bibr79-aph.1C338","first-page":"II-591","volume":"102","author":"Mukherjee D","year":"2000","journal-title":"Circulation"},{"key":"bibr80-aph.1C338","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.7.853"},{"key":"bibr81-aph.1C338","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(00)01044-5","volume":"37","author":"Smith SC","year":"2001","journal-title":"J Am Coll Cardiol"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:08Z","timestamp":1777374428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1345\/aph.1C338"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c338","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}